(+) ACHN, Reports interim results from Phase II trial of its ACH-3102 drug candidate, with all 12 patients taking the drug combined with Gilead Sciences ( GILD ) Sovaldi Hep C treatment showed no detectable traces of the virus after four weeks. Stocks ended mixed Friday, with consumer and technology shares rebounding just enough to lift the Nasdaq Composite index back to positive territory by the close. Shares slumped at mid-day, giving back earlier advances that followed tame inflation data, after reports of renewed fighting in Ukraine hit.